

Carbon Reduction Plan

Supplier name: Orion Pharma (UK) Ltd.

Publication date: March 2024

Commitment to achieving Net Zero

Orion Pharma (UK) Ltd. as part of Orion Corporation is committed to achieving Net Zero emissions by 2050 for emissions scopes 1, 2 and 3.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2023	
Additional Details relating to the Baseline Emissions calculations.	
<p>The greenhouse gas emissions information provided in this CRP consists of the global, parent company level emissions. Orion will further develop its climate reporting capabilities and explore options to provide emissions information of Orion Pharma (UK) Ltd. in future CRP submissions.</p> <p>Due to an acquisition in 2022, the baseline year is the most recent full year (2023) as previous years' emissions calculations would not be fully comparable.</p>	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	5,511
Scope 2	8,429 (market-based method, preferred) 11,726 (location-based method)
Scope 3 (Included Sources)	417,455 Including the following emissions categories: <ol style="list-style-type: none"> 1. Purchased goods and services 2. Capital goods 3. Fuel and energy- related activities 4. Upstream transportation and distribution 5. Waste generated in operations 6. Business travel

	<ul style="list-style-type: none"> 7. Employee commuting 8. Upstream leased assets 9. Downstream transportation and distribution 10. Processing of sold products 11. Use of sold products 12. End-of-life treatment of sold products 13. Downstream leased assets
Total Emissions	431,395 (market-based method, preferred) 434,692 (location-based method)

Current Emissions Reporting

Reporting Year: 2023	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	5,511
Scope 2	8,429 (market-based method, preferred) 11,726 (location-based method)
Scope 3 (Included Sources)	<p>417,455</p> <p>Including the following emissions categories:</p> <ul style="list-style-type: none"> 1. Purchased goods and services 2. Capital goods 3. Fuel and energy- related activities 4. Upstream transportation and distribution 5. Waste generated in operations 6. Business travel 7. Employee commuting 8. Upstream leased assets 9. Downstream transportation and distribution 10. Processing of sold products 11. Use of sold products 12. End-of-life treatment of sold products 13. Downstream leased assets
Total Emissions	431,395 (market-based method, preferred) 434,692 (location-based method)

Emissions reduction targets

In order to continue our progress to achieving Net Zero by 2050, we have adopted the following carbon reduction targets. These targets are set at the parent-company level, but they also align with Orion Pharma (UK) Ltd.

- Orion Corporation aims to achieve carbon neutrality in our own operations by 2030.
- An intermediate target, a reduction of our own greenhouse gas emissions by 75% by 2025 compared to our, slightly older, 2016 baseline.

Also, Orion is currently committed to set near-term Science Based Targets and we expect to send our targets for validation during the first half of 2024.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives:

We continue to systematically implement measures meant to promote energy efficiency and reduce our use of purchased energy and overall, our GHG emissions. Measures below include those with Orion Pharma (UK) Ltd. relevance, in addition to Orion Corporation.

- Orion Pharma UK Ltd. head office in Reading uses 100% renewable electricity.
- EV's are being purchased to electrify our vehicle fleet.
- Suppliers and partners are required to commit to Orion's Third Party Code of Conduct. Orion's Third Party Code of Conduct includes environmental criteria, which requires the Third Party to monitor and reduce its GHG emissions. By the end of 2023, 99% of Orion's active suppliers of packaging materials, raw materials and products had confirmed their adherence to the Third Party Code of Conduct globally.
- Orion has conducted product level life cycle assessments for its dry powder inhalers¹. Orion's dry powder inhalers are sold worldwide, including by Orion Pharma (UK) Ltd. in the UK. Based on these assessments Orion has built an understanding of the environmental impact and identified where reduction efforts should be focused on our way to net-zero.
- Encouraging agile working and environmentally friendly traveling options, including commuting and business travel.
- Create awareness and promote an environmental culture within the organisation enabling employees to take the environment into consideration in their day-to-day.

In the future we hope to implement further measures such as:

- Further improve our emissions calculations, especially in Scope 3, to identify opportunities for further emissions reductions.
- A vehicle fleet consisting only of EV's.
- Carbon neutral employee commuting and business travel within the UK.

Most of Orion's own emissions (Scope 1&2) are generated in manufacturing sites. All of Orion's manufacturing sites are located outside the UK. More large-scale investments are systematically made at the group-level to improve our environmental performance of these manufacturing sites. Measures include, for example, electrifying processes and heating and cooling via heat pumps. More information is available at Orion's website².

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard³ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting⁴.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard⁵.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors of Orion Pharma (UK) Ltd.

Signed on behalf of the Supplier:

DocuSigned by:
Olli Huotari
Signer Name: Olli Huotari
Signing Reason: I approve this document
Signing Time: 08-Apr-2024 | 5:49 PM EEDT
CCE8ECE18DE4483CB36802A38C3D9AD1

DocuSigned by:
Liisa Hurme
Signer Name: Liisa Hurme
Signing Reason: I approve this document
Signing Time: 09-Apr-2024 | 3:51 PM EEDT
B38FAE0703D94E43BF20B04F19458686

Member of the Board of Directors
of Orion Pharma (UK) Ltd

Chair of the Board of Directors
of Orion Pharma (UK) Ltd

Date: 8th of April 2024

¹ <https://www.orion.fi/en/sustainability/environment/environmental-impacts-of-operations/carbon-footprint-assessment-of-orions-dry-powder-inhalers/>

² <https://www.orion.fi/en/sustainability/>

³ <https://ghgprotocol.org/corporate-standard>

⁴ <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

⁵ <https://ghgprotocol.org/standards/scope-3-standard>